cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Mirum Pharmaceuticals Inc
6 own
3 watching
Current Price
$47.53
$-1.12
(-2.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,231.32M
52-Week High
52-Week High
49.27000
52-Week Low
52-Week Low
23.14000
Average Volume
Average Volume
0.44M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,231.32M
icon52-Week High49.27000
icon52-Week Low23.14000
iconAverage Volume0.44M
iconDividend Yield--
iconP/E Ratio--
What does the Mirum Pharmaceuticals Inc do?
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Read More
How much money does Mirum Pharmaceuticals Inc make?
News & Events about Mirum Pharmaceuticals Inc.
Business Wire
1 year ago
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria. The congress presentations feature new analyses from the LIVMARLI (maralixibat) oral solution MARCH-PFIC study...
Business Wire
1 year ago
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from LIVMARLI (maralixibat) oral solution clinical studies evaluating patients with Alagille syndrome (ALGS) were published in Hepatology. LIVMARLI is the first and only approved treatment for cholestatic pruritus in patients with...
Business Wire
1 year ago
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 9, 2023, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,150 shares of common stock and 22,030 restricted stock units (RSUs) to nine new...
Business Wire
1 year ago
Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the notes) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act...
Business Wire
1 year ago
Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the notes) in a private offering to qualified institutional buyers pursuant to Rule 144A...
Frequently Asked Questions
Frequently Asked Questions
What is Mirum Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Mirum Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Mirum Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Mirum Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Mirum Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Mirum Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Mirum Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Mirum Pharmaceuticals Inc?
plus_minus_icon
What percentage is Mirum Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Mirum Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$47.53
$-1.12
(-2.3%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
$19.93
$-0.03 (-0.15 %)
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC
$12.98
$-0.25 (-1.89 %)
Annexon Inc
Annexon Inc
$4.13
$-0.11 (-2.59 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$13.16
$-0.17 (-1.28 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
$19.93
$-0.03 (-0.15 %)
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC
$12.98
$-0.25 (-1.89 %)
Annexon Inc
Annexon Inc
$4.13
$-0.11 (-2.59 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$13.16
$-0.17 (-1.28 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00